摘要: Prostate cancer (PCa) is one of the most common solid cancers and important causes morbidity mortality worldwide in men. So far, several efforts have been devoted to identify prostate biomarkers, which allow a discrimination between indolent clinically significant diseases, however with scarce results. The prostate-specific antigen (PSA) still remains marker choice for PCa diagnosis, prognosis, «active surveillance». Thus, sensitive specific independent indicator, easy screen blood or urine not available. This review will provide new insight into role previous (i.e. PSA) use separately combination screening early detection programs.
core.ac.uk
uzh.ch
metapress.com参考文章(0)